MYCN and neuroblastoma: Since the degradation of N-MYC is regulated in part by a kinase-independent function of Aurora-A, CD532, a conformation-disrupting inhibitor of Aurora-A, acts as a more potent N-MYC inhibitor than the kinase activity inhibitor MLN8237 in neuroblastoma (126).